Scottish Medicines Consortium



transdermal fentanyl (Durogesic D Trans Transdermal Patches) 12mcg/hr (No. 250/06) Janssen-Cilag Ltd Product Update

7 April 2006

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises the NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

transdermal fentanyl (Durogesic D Trans⁰ patches) 12 mcg/hour is accepted for restricted use within NHS Scotland for patients with chronic intractable pain due to non-malignant conditions.

It should be considered as a second-line alternative, reserved for patients whose pain has initially been controlled by oral means, the pain being stable. Its use should focus on patients who have difficulty swallowing or have problems with opiate-induced constipation.

The new strength allows greater flexibility in dose titration without a substantial impact on price compared with the range of patches previously available. However, it remains significantly more expensive than oral therapy.

SMC has not assessed transdermal fentanyl in its original indication for intractable pain due to cancer.

Chairman Scottish Medicines Consortium

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 15 February 2006.